Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin’s lymphoma

FOXP3+ regulatory T-cells represent important modulators of lymphoma/host microenvironment. Their number may represent a positive prognostic factor in patients with germinal center-like diffuse large B-cell lymphoma, follicular lymphoma, and classical Hodgkin's lymphoma. Background The tumor microenvironment is important for the behavior of cancer. We assessed the distribution and biological significance of FOXP3+ regulatory T-cells (Treg) in lymphomas. Design and Methods The absolute number of intratumoral FOXP3+ cells was immunohistochemically studied on lymphoma tissue microarrays from 1019 cases of different types of lymphomas and correlated to phenotypic and clinical parameters in uni- and multivariate models. Receiver operating characteristic -curves were used to determine prognostic cut-off values of FOXP3+ cell density. Results Of the 1019 cases, 926 (91%) were evaluable. FOXP3+ cell density varied between the lymphoma entities, and was highest in follicular lymphoma. An increased number of tumor-infiltrating FOXP3+ cells over the receiver operating characteristic-determined cut-offs positively influenced both disease-specific and failure-free survival in follicular lymphoma (p=0.053) and disease-specific survival in germinal center-like diffuse large B-cell lymphoma (p=0.051) and overall and failure-free survival in classical Hodgkin’s lymphoma (p=0.004), but had a negative prognostic effect in non-germinal center diffuse large B-cell lymphoma (p=0.059). In a Cox regression model, considering stage and age, the amount of FOXP3+ cells was of independent prognostic significance for failure-free survival in classical Hodgkin’s lymphoma and of borderline significance for overall survival in classical Hodgkin’s lymphoma and disease-specific survival in germinal center-like and non-germinal center diffuse large B-cell lymphoma. Conclusions FOXP3+ cells represent important lymphoma/host microenvironment modulators. Assessment of FOXP3+ cell density can contribute to the prediction of outcome in diffuse large B-cell lymphoma, fallicular lymphoma and classical Hodgkin’s lymphoma.

[1]  C. Berek,et al.  The dynamic structure of the germinal center. , 1998, Immunology today.

[2]  S. Kim-Schulze,et al.  The tumour microenvironment and implications for cancer immunotherapy , 2006, Expert opinion on biological therapy.

[3]  L. Staudt,et al.  Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. , 2004, Blood.

[4]  S. Ansell,et al.  Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma. , 2005, Blood.

[5]  M. Wasik,et al.  Nucleophosmin/anaplastic lymphoma kinase (NPM/ALK) oncoprotein induces the T regulatory cell phenotype by activating STAT3. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[6]  M. Beyer,et al.  Regulatory T cells in cancer. , 2006, Blood.

[7]  T. Papadopoulos,et al.  Rare expression of BSAP (PAX-5) in mature T-cell lymphomas , 2007, Modern Pathology.

[8]  M. Fiegl,et al.  Diffuse Large B-Cell Lymphoma with Overexpression of Cyclin E Substantiates Poor Standard Treatment Response and Inferior Outcome , 2006, Clinical Cancer Research.

[9]  C. Addey,et al.  Regulatory T Cells, Derived from Naïve CD4+CD25− T Cells by In Vitro Foxp3 Gene Transfer, Can Induce Transplantation Tolerance , 2005, Transplantation.

[10]  Giovanna Roncador,et al.  Outcome in Hodgkin's Lymphoma Can Be Predicted from the Presence of Accompanying Cytotoxic and Regulatory T Cells , 2005, Clinical Cancer Research.

[11]  T. Nomura,et al.  Control of Regulatory T Cell Development by the Transcription Factor Foxp3 , 2002 .

[12]  H. Stein,et al.  Analysis of FOXP3 protein expression in human CD4(+)CD25(+) regulatory T cells at the single-cell level. , 2006, European journal of immunology.

[13]  N. Krug,et al.  The IL-6R alpha chain controls lung CD4+CD25+ Treg development and function during allergic airway inflammation in vivo. , 2005, The Journal of clinical investigation.

[14]  L. Morel,et al.  IL-6 Produced by Dendritic Cells from Lupus-Prone Mice Inhibits CD4+CD25+ T Cell Regulatory Functions1 , 2007, The Journal of Immunology.

[15]  H. Johnsen,et al.  Serum levels of inflammatory cytokines at diagnosis correlate to the bcl‐6 and CD10 defined germinal centre (GC) phenotype and bcl‐2 expression in patients with diffuse large B‐cell lymphoma , 2005, British journal of haematology.

[16]  Christian Gisselbrecht,et al.  The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells. , 2007, Blood.

[17]  C. Klemke,et al.  Paucity of FOXP3+ cells in skin and peripheral blood distinguishes Sézary syndrome from other cutaneous T-cell lymphomas , 2006, Leukemia.

[18]  Vincent C. Manganiello,et al.  Foxp3-dependent programme of regulatory T-cell differentiation , 2007, Nature.

[19]  P. Pereira,et al.  T Cell‐Dependent B Cell Activation , 1984, Immunological reviews.

[20]  E. Shevach,et al.  Activated CD4+CD25+ T cells selectively kill B lymphocytes. , 2006, Blood.

[21]  S. Pileri,et al.  Rare expression of KIT (CD117) in lymphomas: a tissue microarray study of 1166 cases , 2004, Histopathology.

[22]  P. Lipsky,et al.  TNF downmodulates the function of human CD4+CD25hi T-regulatory cells. , 2006, Blood.

[23]  M. Fiegl,et al.  Epidemiology of non-Hodgkin lymphomas in Tyrol/Austria from 1991 to 2000 , 2006, Journal of Clinical Pathology.

[24]  S. Pileri,et al.  Prognostic significance of CD44 expression in diffuse large B cell lymphoma of activated and germinal centre B cell-like types: a tissue microarray analysis of 90 cases , 2003, Journal of clinical pathology.

[25]  Wei-Zen Wei,et al.  Anti-tumor immunity and autoimmunity: a balancing act of regulatory T cells , 2004, Cancer Immunology, Immunotherapy.

[26]  Emili Montserrat,et al.  High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. , 2006, Blood.

[27]  P. Hillsamer,et al.  Regulatory T cells can migrate to follicles upon T cell activation and suppress GC-Th cells and GC-Th cell-driven B cell responses. , 2004, The Journal of clinical investigation.

[28]  Fiona Powrie,et al.  Analysis of FOXP3 protein expression in human CD4+CD25+ regulatory T cells at the single‐cell level , 2005, European journal of immunology.

[29]  H. Rahn,et al.  Follicular B helper T cell activity is confined to CXCR5hiICOShi CD4 T cells and is independent of CD57 expression , 2006, European journal of immunology.

[30]  D. de Jong.  Molecular pathogenesis of follicular lymphoma: a cross talk of genetic and immunologic factors. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  H. Nilsson‐Ehle,et al.  The number of tumour‐infiltrating TIA‐1+ cytotoxic T cells but not FOXP3+ regulatory T cells predicts outcome in diffuse large B‐cell lymphoma , 2007, British journal of haematology.

[32]  Martin W. Bunder,et al.  The inconsistency of , 1976, Journal of Symbolic Logic.

[33]  L. Staudt,et al.  Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. , 2004, The New England journal of medicine.

[34]  E. Heinen,et al.  Human Germinal Center CD4+ CD57+ T Cells Act Differently On B Cells Than Do Classical T-Helper Cells , 1995, Developmental immunology.

[35]  P. Vyas,et al.  Pathology and genetics: Tumours of haematopoietic and lymphoid tissues , 2001 .

[36]  N. Perkins,et al.  The inconsistency of "optimal" cutpoints obtained using two criteria based on the receiver operating characteristic curve. , 2006, American journal of epidemiology.

[37]  A. Banham,et al.  Cutting Edge: Direct Suppression of B Cells by CD4+CD25+ Regulatory T Cells1 , 2005, The Journal of Immunology.

[38]  Marylène Lejeune,et al.  Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma patients. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  A. Tzankov,et al.  Pathobiology of Classical Hodgkin Lymphoma , 2006, Pathobiology.

[40]  B. Zheng,et al.  Germinal Center Helper T Cells Are Dual Functional Regulatory Cells with Suppressive Activity to Conventional CD4+ T Cells , 2007, The Journal of Immunology.

[41]  G. Schaefer,et al.  Angiogenesis in nodal B cell lymphomas: a high throughput study , 2006, Journal of Clinical Pathology.

[42]  C. Borrebaeck,et al.  Immunoglobulin production induced by CD57+ GC-derived helper T cells in vitro requires addition of exogenous IL-2. , 1996, Cellular immunology.

[43]  R. Barker,et al.  Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. , 2004, Blood.

[44]  M. Calaminici,et al.  Number of CD4+ cells and location of forkhead box protein P3-positive cells in diagnostic follicular lymphoma tissue microarrays correlates with outcome. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  Alexandar Tzankov,et al.  Tissue microarray technology: principles, pitfalls and perspectives—lessons learned from hematological malignancies , 2005, Experimental Gerontology.

[46]  E. Jaffe.  Pathology and Genetics: Tumours of Haematopoietic and Lymphoid Tissues , 2003 .

[47]  N. Munshi,et al.  Dysfunctional T regulatory cells in multiple myeloma. , 2006, Blood.

[48]  A. Rudensky,et al.  Regulatory T cell lineage specification by the forkhead transcription factor foxp3. , 2005, Immunity.